GPRC5S x CD3 bispecific antibodies

被引：0
|
作者：
Stretton, Owen
机构：
来源：
LANCET HAEMATOLOGY | 2022年 / 9卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E558 / E558
页数：1
相关论文
共 50 条
  • [11] A novel T cell-redirecting anti-GPRC5D x CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models
    Tomita, Urara
    Ishimoto, Yoko
    Ri, Masaki
    Kawase, Yumi
    Hizukuri, Yoshiyuki
    Maru, Chikako
    Nanai, Kayoko
    Nakamura, Ryuichi
    Nakayama, Makiko
    Oguchi-Oshima, Keiko
    Sumi, Hiroyuki
    Ohtsuka, Toshiaki
    Iida, Shinsuke
    Agatsuma, Toshinori
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [12] Characterization and management of oral and dermatological toxicities in patients receiving the CD3 X GPRC5D bispecific antibody talquetamab for the treatment of relapsed/refractory multiple myeloma
    Aronson, Elizabeth
    Purcell, Kiah
    Aponte, Annel
    Louw, Karen
    Catamero, Donna
    Lamb, Angela
    Kirke, Diana
    Lucas, Aimee
    Jagannath, Sundar
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S195 - S195
  • [13] CD20 x CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
    Liu, Xinyuan
    Zhao, Juanjuan
    Guo, Xiangqian
    Song, Yongping
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [14] CD3 x CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma
    Manzke, O
    Titzer, S
    Tesch, H
    Diehl, V
    Bohlen, H
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1997, 45 (3-4) : 198 - 202
  • [15] Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies
    Reed, Daniel R.
    Lum, Lawrence G.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (08) : 761 - 772
  • [16] Eradication of gastric carcinoma cells by targeting EpCam and CD3 using bispecific/trifunctional antibodies
    Chaudry, MA
    Sales, K
    Yang, W
    Ruf, P
    Lindhofer, H
    Winslet, M
    BRITISH JOURNAL OF SURGERY, 2005, 92 (10) : 1326 - 1327
  • [17] The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 Arm
    Suurs, Frans, V
    Lorenczewski, Grit
    Stienen, Sabine
    Friedrich, Matthias
    de Vries, Elisabeth G. E.
    de Groot, Derk Jan A.
    Lub-de Hooge, Marjolijn N.
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (11) : 1594 - 1601
  • [18] CD3 x CD28 cross-interacting bispecific antibodies improve tumor cell dependent T-cell activation
    Willems, A
    Schoonooghe, S
    Eeckhout, D
    De Jaeger, G
    Grooten, J
    Mertens, N
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (11) : 1059 - 1071
  • [19] Characterization and Management of Oral and Dermatological Toxicities in Patients Receiving the CD3 X GPRC5D Bispecific Antibody Talquetamab (JNJ-64407564) for the Treatment of Relapsed and/or Refractory Multiple Myeloma
    Mancia, Stefania Stefania
    Farrell, Annamaria
    Louw, Karen
    Florendo, Erika
    Aronson, Elizabeth
    Purcell, Kiah
    Catamero, Donna D.
    Escalon, Juliet
    Thomas, Joanne
    Aponte, Annel
    Lamb, Angela
    Kirke, Diana
    Lucas, Aimee
    Jagannath, Sundar
    Cho, Hearn Jay
    Parekh, Samir
    Richter, Joshua
    Sanchez, Larysa
    Chari, Ajai
    BLOOD, 2021, 138
  • [20] A novel T cell-redirecting anti-GPRC5D × CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models
    Urara Tomita
    Yoko Ishimoto
    Masaki Ri
    Yumi Kawase
    Yoshiyuki Hizukuri
    Chikako Maru
    Kayoko Nanai
    Ryuichi Nakamura
    Makiko Nakayama
    Keiko Oguchi-Oshima
    Hiroyuki Sumi
    Toshiaki Ohtsuka
    Shinsuke Iida
    Toshinori Agatsuma
    Scientific Reports, 14
12345